Kappa/Lambda Quantitative Free Light Chains with Ratio, Serum
Also known as: KAP/LAM F
Use
The test aids in the evaluation and management of multiple myeloma and related plasma cell disorders. It is indicated for the diagnosis of patients with oligosecretory or nonsecretory multiple myeloma and light chain amyloidosis. The assay is highly sensitive and can detect increasing concentrations of monoclonal free kappa or free lambda light chains, which is crucial in patients with evolving or relapsing myelomas.
Special Instructions
Not provided.
Limitations
Undetected antigen excess is a rare event but cannot be excluded. Therefore, free light chain results should always be interpreted in conjunction with other clinical and laboratory findings to ensure accurate diagnosis and management.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Other)
Biomarkers
Kappa Qnt Free Light Chains
AnalyteKappa/Lambda Free Light Chain Ratio
AnalyteLambda Qnt Free Light Chains
Analyte
LOINC Codes
- 33944-0 - Lambda LC Free SerPl-mCnc
- 36916-5 - Kappa LC Free Ser-mCnc
- 80517-6 - Kappa LC Free/Lambda Free Ser Neph
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate from cells ASAP or within 2 hours of collection.
Storage Instructions
Refrigerated storage is required.
Causes for Rejection
Plasma or grossly hemolyzed and lipemic samples
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 3 weeks |
| Frozen | 6 months |
Other tests from different labs that may be relevant